Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26431425 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL20710104 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL25857291 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL5297053 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL12869205 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL26039290 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL25857292 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL25857295 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL25857288 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL9810706 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| WO-2021231615-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | SMN1; SMN2 3490/4885KCNH2 2924/4885OPRK1 2077/4885 |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | SMN1; SMN2 9/4885KCNH2 4241/4885OPRK1 1388/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | SMN1; SMN2 9/4885KCNH2 4241/4885OPRK1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.